NuCana PLC (NCNA)

NASDAQ
Currency in USD
0.050
-0.010(-16.75%)
Closed·
Pre Market
0.052+0.002(+4.18%)
·
NCNA Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
NCNA is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.0500.061
52 wk Range
0.03310.790
Key Statistics
Edit
Prev. Close
0.05
Open
0.06
Day's Range
0.05-0.061
52 wk Range
0.033-10.79
Volume
227.32M
Average Volume (3m)
197.67M
1-Year Change
-98.41%
Book Value / Share
0.89
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
NCNA Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a low Price / Book multiple

NuCana PLC News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

NuCana Company Profile

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company is developing medicines to overcome the limitations of nucleoside analogs and generate anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer; Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer; and Phase 1 modular clinical trial for patients with advanced solid tumors and lung cancer. The company is also developing NUC-7738, a ProTide transformation of 3’-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. The company has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is based in Edinburgh, the United Kingdom.

Compare NCNA to Peers and Sector

Metrics to compare
NCNA
Peers
Sector
Relationship
P/E Ratio
0.0x−3.5x−0.5x
PEG Ratio
0.00−0.030.00
Price/Book
0.1x3.4x2.6x
Price / LTM Sales
-47.2x3.2x
Upside (Analyst Target)
-200.0%45.9%
Fair Value Upside
Unlock20.9%7.0%Unlock

Earnings

Latest Release
Jun 02, 2025
EPS / Forecast
-0.41 / -13.00
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

NCNA Income Statement

FAQ

What Is the NuCana (NCNA) Stock Price Today?

The NuCana stock price today is 0.05.

What Stock Exchange Does NuCana Trade On?

NuCana is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for NuCana?

The stock symbol for NuCana is "NCNA."

What Is the NuCana Market Cap?

As of today, NuCana market cap is 304.06K.

What Is NuCana's Earnings Per Share (TTM)?

The NuCana EPS (TTM) is -3.70.

From a Technical Analysis Perspective, Is NCNA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has NuCana Stock Split?

NuCana has split 1 times.

How Many Employees Does NuCana Have?

NuCana has 21 employees.

What is the current trading status of NuCana (NCNA)?

As of 14 Jul 2025, NuCana (NCNA) is trading at a price of 0.05, with a previous close of 0.05. The stock has fluctuated within a day range of 0.05 to 0.06, while its 52-week range spans from 0.03 to 10.79.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.